News items Chemotherapie gericht losklikken leidt tot goede resultaten in muizen

4 May 2018

Tagworks Pharmaceuticals, based at Radboud university medical center, has developed a new technique for the targeted delivery of chemotherapy for tumors in cases where this was previously very difficult. By way of the controlled ‘click-to-release’ of the chemotherapy drug from its tumor-binding carrier, the chemotherapy can be activated at the right location. The company is publishing the results of studies in mice that have been treated with this method in Nature Communications.

Antibody Drug Conjugates (ADCs) are relatively new anti-cancer drugs. They consist of an antibody to which a cell-killing molecule (chemotherapy) is attached. Antibodies can recognize and bind to certain receptors (the ‘hands’ on the outside of a cell) in a very targeted way. The antibody in an ADC is designed to adhere exclusively to receptors that are characteristic of a tumor cell. The chemotherapy drug is not released until the receptor has brought the entire structure into the cell, and then the chemotherapy drug can do its job.
 
ADCs are currently already used for the treatment of lymphoma and metastatic breast cancer. “These ADCs work very well,” says Marc Robillard of Tagworks Pharmaceuticals, a company based at Radboud university medical center. “But for many other tumors, including colon cancer and ovarian cancer, this method is not yet applicable. The problem is that there are not many suitable cancer-specific receptors that automatically drag such an ADC into the cell, and if the ADC gets stuck on the outside, the chemotherapy drug will not be released and therefore can’t do its job.”
 
Chemotherapy drug released
It is vital to ensure that the chemotherapy drug is also released if the ADC remains on the outside of the tumor cells. To achieve this objective, Tagworks has designed a smart variant of the ADCs. The ADC is injected and then binds to the receptors on the tumor cells. After a day or two, the tumor is filled with these ADCs. So far, this is nothing new. Robillard: “Our innovation is that we inject a second component that ‘click-releases’ the chemotherapy drug from the ADC. As a result, a large quantity of chemotherapy is released very quickly, attacking the tumor. This method will hopefully enable us to treat many more types of cancer.”
 
Effective in mice
The first results of this new ‘click-to-release’ method in mice have now been published in Nature Communications. Robillard: “We studied ovarian cancer and an aggressive form of colon cancer. In both cases we observed a pronounced anticancer effect. For control purposes, we also applied a ‘traditional’ ADC, i.e., without the second component that causes the chemotherapy drug to release, but this approach had no therapeutic effect  in these forms of cancer.”
 
Cooperation
In Nijmegen, Tagworks collaborates with a variety of research groups, Technology Centers and Research Facilities, which have been specifically set up for cooperation with the business community, including the Radboudumc Technology Center for Mass Spectrometry. In addition, Tagworks cooperates with specialized small and medium-sized enterprises that are also co-authors of the publication. According to Robillard, this illustrates the importance of cooperation. “Developing new drugs for cancer is very complex and requires the expertise of specialists. No party can do this by itself. I believe this result is a fine example of how you can maximize the innovative power of small and medium-sized businesses by joining forces and connecting with the advanced facilities and high-quality knowledge of institutions such as Radboud university medical center and Radboud University.” 

More information


Marcel Wortel

information officer

(024) 81 87389


Pieter Lomans

information officer

(024) 81 87012

Related news items


Mark van den Boogaard received the Dr. Peter Moleman penning

18 October 2018

Last week Mark van den Boogaard received the Dr. Peter Moleman penning for best article in the field of psycho-pharmacy published in the last 2 years.

read more

UN High-Level Meeting on NCDs Oral Health Event

18 October 2018

In the context of the United Nations General Assembly 3rd High-level Meeting on NCDs, oral health was addressed during a special side event on 28 September 2018.

read more

Symposium Medical care for people with intellectual disabilities

18 October 2018

On Tuesday 4 December Esther Bakker will defend her thesis ‘A Pro-active health assessment instrument for people with intellectual disabilities – towards reducing health inequities’. Prior to her defense, a symposium will be held.

read more

Very few similarities between the brains of schizophrenia patients Research at group level says little about the individual patient

16 October 2018

Patients with a diagnosis of schizophrenia are a heterogenous group with large differences between individuals. Researchers at the Radboudumc showed that only a negligible number of identical features in the brain occur in more than two percent of patients.

read more

New collaboration with Ruhr-University Bochum to unravel how stress affects memory quality

11 October 2018

A new collaborative project with the Ruhr-University Bochum will investigate how stress hormones alter the course and quality of formation of long-term memories.

read more

A personal touch of Cenna van Manen

11 October 2018

In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t! This week: Cenna van Manen.

read more
  • Go to